NuVasive — Q1 2017 Earnings Presentation
16 slides from NuVasive's earnings presentation, Apr 25, 2017
Slide 1: Q1 2017 Results Supplemental Presentation to Earnings Press Release
Q1 2017 Results Supplemental Presentation to Earnings Press Release April 25, 2017 Exhibit 99.2
Slide 2: Forward-Looking Statements
Forward-Looking Statements NuVasive cautions you that statements included in this presentation that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could caus
Slide 3: Non-GAAP Financial Measures
Non-GAAP Financial Measures Management uses certain non-GAAP financial measures such as non-GAAP earnings per share, non-GAAP net income, non-GAAP operating expenses and non-GAAP operating profit margin, which exclude amortization of intangible assets, non-cash purchase accounting adjustments on acq
Slide 4: Q1 2017 Performance
Q1 2017 Performance Reported year-over-year revenue growth of 16.2% to $249.9 million, or 16.0% on a constant currency basis. Delivered GAAP operating profit margin of 9.3%; non-GAAP operating profit margin of 14.1%. Drove GAAP diluted earnings per share of $0.22; non-GAAP diluted EPS up 11.8% to $0
Slide 5: First Quarter 2017 Revenue Highlights
First Quarter 2017 Revenue Highlights 10% U.S. SPINAL HARDWARE Includes All Implants, Fixation, MAGEC® & PRECICE® 20% 34%* * Constant currency basis U.S. SURGICAL SUPPORT Includes Biologics, IOM Services & Disposables INTERNATIONAL Includes Puerto Rico Key Performance Factors Continued Adoption of C
Slide 6: First Quarter 2017 P&L Performance
First Quarter 2017 P&L Performance Non-GAAP Measures 1Q17 Actuals 1Q17 YoY Performance Factors Gross Margin 75.3% ↓ 180 bps negatively impacted by lower gross margin profile of the Biotronic business (~240 bps) Sales, Marketing & Admin. 56.2% ↓ 180 bps improvement from prior year impacted by lower S
Slide 7: Strong History of Growth and Profitability
* NuVasive financial performance guidance as of April 25, 2017. Global Revenue (In Millions) Non-GAAP Operating Profit Margin ~570 Basis Point Improvement $1,065* 11.4% 15.4% 16.1% 17.1%* Strong History of Growth and Profitability DISCIPLINED EXECUTION OF STRATEGY DRIVES EXCEPTIONAL RESULTS
Slide 8: 2017 Technology Innovations
8 2017 Technology Innovations* Modulus XLIF implant a novel, fully porous titanium implant created through an additive, 3D-printed manufacturing process Expandable implants for optimal fusion opportunity Designed to reduce surgical radiation Internal solution for fractures failing to heal due to com
Slide 9: Investment in U.S. Manufacturing
New ‘all digital’, 180,000 sq. ft. facility is on-line and supporting select implants and instruments Produced 80,000+ parts out of facility in Q1 2017 Investing ~$45M to construct and equip new facility with state-of-the-art equipment Hiring well underway; expect to employ ~300 high-tech positions
Slide 10: Enhancing Financial Flexibility
Enhancing Financial Flexibility Line of Credit Expanded Expands existing revolving line of credit, from $150 million up to $500 million. Demonstrates the Company’s opportunistic approach to its capital structure, and provides for a five-year term at reasonable borrowing rates. Allows greater flexibi
Slide 11: Driving ~20% CAGR in Adjusted EBITDA Improvements
Driving ~20% CAGR in Adjusted EBITDA Improvements * NuVasive financial performance guidance as of April 25, 2017. Incremental focus on improving the working capital profile and CapEx spending will drive incremental gains in the free cash flow profile of the Company. Disciplined approach to driving p
Slide 12: Driving Improved Tax Rate
Driving Improved Tax Rate Focused on reducing tax rate through international scale and domestic tax planning Opportunity to drive non-GAAP effective tax rate lower by ~1,400 bps over 5 years. OPERATING IMPROVEMENTS TAKING HOLD Global tax planning initiatives are playing through: International scale
Slide 13: FY17 Guidance
* NuVasive financial performance guidance as of April 25, 2017; ^Constant currency FY17 Guidance Performance Drivers Revenues As reported ~$1.065B, ~11.7% YoY growth^ ~$61M full year of Biotronic contribution; ~$10M currency headwind U.S. Spinal Hardware U.S. Surgical Support International ~8% YoY g
Slide 14: Q2 2017 Performance Expectations
Q2 2017 $262M Revenue Non-GAAP operating profit margin of 15.5% Q2 2017 Performance Expectations* PERFORMANCE EXPECTATIONS FOR MODELING PURPOSES ~12.3% Reported Ex FX ~6.5% Pro-forma Ex FX Non-GAAP Earnings per share of $0.44 * NuVasive financial performance guidance as of April 25, 2017; growth rat
Slide 15: Why Invest in NuVasive
Growing revenues at multiples of market in high single-digit range* Long-term non-GAAP operating profit margins expanding to ~25% and adjusted EBITDA margin to ~32%* Drive change in tax rate from high 30%’s to high 20%’s* Optimizing tax structure to drive EPS growth 2x the rate of revenue growth* Se
Slide 16: Slide 16